- Receptor‑interacting serine/threonine‑protein kinase 1 (RIPK1) is a multifunctional signalling protein that integrates cues from death receptors, pattern‑recognition receptors and cellular stress pathways to determine whether a cell survives, undergoes apoptosis or triggers necroptosis. RIPK1 acts as a molecular switch: under homeostatic conditions it promotes cell survival and inflammation, but under specific stress conditions it drives regulated cell death. This duality makes RIPK1 a central node in immunity, inflammation and cell‑death biology.
- RIPK1 contains three major functional regions: an N‑terminal kinase domain, an intermediate region with a RIP homotypic interaction motif (RHIM), and a C‑terminal death domain. These domains allow RIPK1 to interact with TNFR1, Fas, TRAIL receptors, TRIF, RIPK3 and other signalling proteins. The versatility of RIPK1 arises from its ability to form distinct complexes depending on cellular context, post‑translational modifications and stress intensity.
- When TNFR1 is activated by TNF, RIPK1 is recruited to Complex I, a membrane‑associated signalling platform containing TRADD, TRAF2, cIAP1/2 and LUBAC. In this complex, RIPK1 is heavily ubiquitinated, which promotes activation of NF‑κB and MAPK pathways. This leads to transcription of pro‑survival and inflammatory genes, helping cells adapt to stress and maintain tissue homeostasis.
- Under conditions where RIPK1 ubiquitination is impaired—such as loss of cIAPs, LUBAC dysfunction or deubiquitination by CYLD or A20—RIPK1 dissociates from Complex I and forms cytosolic Complex II. Here, RIPK1 interacts with FADD and caspase‑8, promoting apoptosis. This pathway eliminates damaged or infected cells in a controlled, non‑inflammatory manner, linking RIPK1 to apoptosis and programmed cell death.
- When caspase‑8 is inhibited or absent, RIPK1 instead interacts with RIPK3 through their RHIM domains, forming the necrosome, the defining signalling complex of necroptosis. In this pathway, RIPK1’s kinase activity is essential. RIPK3 phosphorylates MLKL, which oligomerises and disrupts the plasma membrane, causing inflammatory cell death. Necroptosis acts as a fail‑safe mechanism during viral infection, inflammation and tissue injury.
- RIPK1 also interfaces with other stress pathways. Severe ER stress can modulate RIPK1 activity through JNK signalling. Oxidative stress influences RIPK1’s kinase activation and its interactions with mitochondrial pathways. Crosstalk with autophagy affects RIPK1 turnover and necrosome stability. These interactions ensure that RIPK1 integrates multiple stress signals before committing the cell to survival or death.
- Dysregulation of RIPK1 contributes to numerous diseases. Excessive RIPK1 kinase activity drives neuroinflammation and neuronal death in Alzheimer’s disease, ALS, Parkinson’s disease and multiple sclerosis. Inflammatory disorders such as IBD, psoriasis and rheumatoid arthritis involve aberrant RIPK1‑mediated cell death and cytokine release. RIPK1 also influences ischemia–reperfusion injury, viral infection responses and cancer biology. Because of its central role, RIPK1 kinase inhibitors (e.g., necrostatins) are being explored as therapeutic agents.
- In summary, RIPK1 is a master regulator of cell fate, balancing survival, apoptosis and necroptosis through context‑dependent signalling complexes. Its ability to integrate inflammatory cues, stress signals and death‑receptor activation makes RIPK1 a pivotal determinant of tissue homeostasis and disease progression. As research advances, RIPK1 continues to emerge as a key therapeutic target in inflammation, neurodegeneration and regulated cell‑death disorders.
